• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
LBT
Click for more information
5.00% 1.9¢

LBT INNOVATIONS LIMITED - Announcements

Market Cap $23.13M  ! watchlist Created with Sketch. Add to my watchlist

LBT Innovations Limited is a medical technology company. The Company is engaged in... LBT Innovations Limited is a medical technology company. The Company is engaged in researching, developing and commercializing technologies for the healthcare and laboratory supply markets and manufacture and sales of the Automated Plate Assessment System (APAS Independence). Its products include APAS Independence, APAS Analysis Modules, APAS-AMR Analysis Module, and APAS PharmaQ. The APAS Independence is a platform technology that automates culture-plate screening and interpretation. The APAS Analysis Modules are the intelligent image analysis software that works together with the APAS Independence to enable the screening of microbiology culture plates. The APAS-AMR Analysis Module uses artificial intelligence mage analysis platform to read and interpret antimicrobial susceptibility tests (ASTs) for the detection of antimicrobial resistance (AMR). The APAS PharmaQC provides automated imaging, analysis and interpretation of microbiology culture plates used in environmental monitoring.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
LBT Initial Director's Interest Notice25/03/19
LBT Change of Director's Interest Notice22/03/19
LBT Final Director's Interest Notice04/03/19
LBT Change of Director's Interest Notice04/03/19
LBT Non-Executive Director Changes01/03/19
LBT Half Yearly Report and AccountsPRICE SENSITIVE26/02/19
LBT Details of Investor Call - 6 February 201905/02/19
LBT Initial Director's Interest Notice04/02/19
LBT Appendix 4C - quarterlyPRICE SENSITIVE31/01/19
LBT Appointment US Based Non-Executive Director Simon Arkell30/01/19
LBT US FDA 510k Submitted for APAS IndependencePRICE SENSITIVE21/12/18
LBT LBT Receives $1.9 Million R&D Tax IncentivePRICE SENSITIVE20/12/18
LBT Expiration of Options10/12/18
LBT LBT Presentation - 121 Tech Investment Conference, SingaporePRICE SENSITIVE03/12/18
LBT Expiration of Options03/12/18
LBT Results of Meeting28/11/18
LBT CEO Presentation - AGM 2018PRICE SENSITIVE28/11/18
LBT Chairman's Address to ShareholdersPRICE SENSITIVE28/11/18
LBT First Placement of APAS Independence into US LabPRICE SENSITIVE26/11/18
LBT Australian Sales UpdatePRICE SENSITIVE26/11/18
LBT Quarterly Activities & Cashflow Report - Appendix 4CPRICE SENSITIVE31/10/18
LBT Notice of Annual General Meeting/Proxy Form26/10/18
LBT Final Director's Interest Notice23/10/18
LBT Change of Director's Interest Notice23/10/18
LBT Cancellation of Options23/10/18
LBT Non-Executive Director Resignation22/10/18
LBT Correction to 2018 Annual Report04/10/18
LBT Appendix 4G27/09/18
LBT Corporate Governance Statement27/09/18
LBT Annual Report to shareholders27/09/18
LBT Company Presentation - Australian Non Deal RoadshowPRICE SENSITIVE17/09/18
LBT Preliminary Final ReportPRICE SENSITIVE30/08/18
LBT Finalisation of SA Government Loan Facility AgreementPRICE SENSITIVE28/08/18
LBT First Commercial Sale of APAS IndependencePRICE SENSITIVE22/08/18
LBT Details of Investor Call - 15 August 201814/08/18
LBT Quarterly Activities & Cash Flow Report - Appendix 4CPRICE SENSITIVE30/07/18
LBT Presentation at 14th Bioshares Biotech Summit27/07/18 download Created with Sketch. 1.7MB
LBT Market UpdatePRICE SENSITIVE29/06/18 download Created with Sketch. 47.64KB
LBT Presentation of APAS at ASM Microbe07/06/18 download Created with Sketch. 164.1KB
LBT Strategic Plan & Asset Review, WoundVuePRICE SENSITIVE06/06/18 download Created with Sketch. 166.01KB
LBT Investor Presentation04/06/18 download Created with Sketch. 1.74MB
LBT Notice Under Section 708A14/05/18
LBT Appendix 3B14/05/18
LBT Completion of Private Placement $7.9M Raised with SPP14/05/18
LBT Ceasing to be a substantial holder09/05/18
LBT Ceasing to be a substantial holder07/05/18
LBT Quarterly Investor Call Details07/05/18
LBT Change of Director's Interest Notice03/05/18
LBT Change of Director's Interest Notice03/05/18
LBT Change of Director's Interest Notice03/05/18
LBT Change of Director's Interest Notice03/05/18
LBT Change of Director's Interest Notice03/05/18
LBT Change of Director's Interest Notice03/05/18
LBT Notice Under Section 708A27/04/18
LBT Appendix 3B27/04/18
LBT Appendix 3B26/04/18
LBT Quarterly Activities & Cash Flow Report - Appendix 4CPRICE SENSITIVE26/04/18
LBT First Placement of APAS Independence into European LabPRICE SENSITIVE24/04/18
LBT Presentation of APAS Evaluation at 28th ECCMID Conference23/04/18
LBT EGM - Results of Meeting18/04/18
LBT EGM - CEO Presentation18/04/18
LBT Appendix 3B10/04/18
LBT Share Purchase Plan Raises $0.49M06/04/18
LBT Notice of Extraordinary General Meeting/Proxy Form16/03/18
LBT Share Purchase Plan Offer DocumentPRICE SENSITIVE14/03/18
LBT NOTICE UNDER SECTION 708A12/03/18
LBT Information under Listing Rule 3.10.5A12/03/18
LBT Appendix 3B12/03/18
LBT $7m Oversubscribed Private Placement & Launch of $1m SPPPRICE SENSITIVE06/03/18
LBT Trading HaltPRICE SENSITIVE02/03/18
LBT Half Yearly Report and AccountsPRICE SENSITIVE26/02/18
LBT LBT Receives $4m Funding from South Australian GovernmentPRICE SENSITIVE19/02/18
LBT Quarterly Activities & Cash Flow Report (Appendix 4C)PRICE SENSITIVE29/01/18
LBT LBT Presentation JP Morgan Biotech Showcase08/01/18
LBT $2.5M Grant Awarded to Advance WoundVue DevelopmentPRICE SENSITIVE07/12/17
LBT Appendix 3B04/12/17
LBT Change of Director's Interest Notice01/12/17
LBT Change of Director's Interest Notice01/12/17
LBT Appendix 3B01/12/17
LBT Completion of Transaction with AutobioPRICE SENSITIVE01/12/17
LBT Results of Meeting29/11/17
LBT CEO Presentation - AGM 201729/11/17
LBT Chairman's Address to Shareholders29/11/17
LBT St Vincent's Hospital Completes APAS Independence EvaluationPRICE SENSITIVE29/11/17
LBT Appendix 4C - quarterlyPRICE SENSITIVE31/10/17
LBT Autobio $2M Placement in LBT & MicroStreak IP TransferPRICE SENSITIVE27/10/17
LBT Notice of Annual General Meeting/Proxy Form27/10/17
LBT LBT Present at AusBiotech Investor Conference24/10/17
LBT LBT Receives $4.2 Million in R&D IncentivesPRICE SENSITIVE09/10/17
LBT Appendix 4G and Corporate Governance Statement29/09/17
LBT Annual Report to shareholders29/09/17
LBT Shareholder Update29/09/17
LBT ST Vincent's Hospital Commences APAS Automated EvaluationPRICE SENSITIVE27/09/17
LBT Initial Director's Interest Notice01/09/17
LBT Initial Director's Interest Notice01/09/17
LBT Preliminary Final ReportPRICE SENSITIVE31/08/17
LBT LBT Innovations Appoints New CFO Ray Ridge25/08/17
LBT LBT's WoundVue Prototype to be used at CALHNPRICE SENSITIVE08/08/17
LBT Final Director's Interest Notice01/08/17
LBT CHANGE OF REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS27/07/17
LBT Initial Director's Interest Notice
25/03/19
LBT Change of Director's Interest Notice
22/03/19
LBT Final Director's Interest Notice
04/03/19
LBT Change of Director's Interest Notice
04/03/19
LBT Non-Executive Director Changes
01/03/19
LBT Half Yearly Report and Accounts
26/02/19PRICE SENSITIVE
LBT Details of Investor Call - 6 February 2019
05/02/19
LBT Initial Director's Interest Notice
04/02/19
LBT Appendix 4C - quarterly
31/01/19PRICE SENSITIVE
LBT Appointment US Based Non-Executive Director Simon Arkell
30/01/19
LBT US FDA 510k Submitted for APAS Independence
21/12/18PRICE SENSITIVE
LBT LBT Receives $1.9 Million R&D Tax Incentive
20/12/18PRICE SENSITIVE
LBT Expiration of Options
10/12/18
LBT LBT Presentation - 121 Tech Investment Conference, Singapore
03/12/18PRICE SENSITIVE
LBT Expiration of Options
03/12/18
LBT Results of Meeting
28/11/18
LBT CEO Presentation - AGM 2018
28/11/18PRICE SENSITIVE
LBT Chairman's Address to Shareholders
28/11/18PRICE SENSITIVE
LBT First Placement of APAS Independence into US Lab
26/11/18PRICE SENSITIVE
LBT Australian Sales Update
26/11/18PRICE SENSITIVE
LBT Quarterly Activities & Cashflow Report - Appendix 4C
31/10/18PRICE SENSITIVE
LBT Notice of Annual General Meeting/Proxy Form
26/10/18
LBT Final Director's Interest Notice
23/10/18
LBT Change of Director's Interest Notice
23/10/18
LBT Cancellation of Options
23/10/18
LBT Non-Executive Director Resignation
22/10/18
LBT Correction to 2018 Annual Report
04/10/18
LBT Appendix 4G
27/09/18
LBT Corporate Governance Statement
27/09/18
LBT Annual Report to shareholders
27/09/18
LBT Company Presentation - Australian Non Deal Roadshow
17/09/18PRICE SENSITIVE
LBT Preliminary Final Report
30/08/18PRICE SENSITIVE
LBT Finalisation of SA Government Loan Facility Agreement
28/08/18PRICE SENSITIVE
LBT First Commercial Sale of APAS Independence
22/08/18PRICE SENSITIVE
LBT Details of Investor Call - 15 August 2018
14/08/18
LBT Quarterly Activities & Cash Flow Report - Appendix 4C
30/07/18PRICE SENSITIVE
LBT Presentation at 14th Bioshares Biotech Summit
27/07/18 download Created with Sketch. 1.7MB
LBT Market Update
29/06/18PRICE SENSITIVE download Created with Sketch. 47.64KB
LBT Presentation of APAS at ASM Microbe
07/06/18 download Created with Sketch. 164.1KB
LBT Strategic Plan & Asset Review, WoundVue
06/06/18PRICE SENSITIVE download Created with Sketch. 166.01KB
LBT Investor Presentation
04/06/18 download Created with Sketch. 1.74MB
LBT Notice Under Section 708A
14/05/18
LBT Appendix 3B
14/05/18
LBT Completion of Private Placement $7.9M Raised with SPP
14/05/18
LBT Ceasing to be a substantial holder
09/05/18
LBT Ceasing to be a substantial holder
07/05/18
LBT Quarterly Investor Call Details
07/05/18
LBT Change of Director's Interest Notice
03/05/18
LBT Change of Director's Interest Notice
03/05/18
LBT Change of Director's Interest Notice
03/05/18
LBT Change of Director's Interest Notice
03/05/18
LBT Change of Director's Interest Notice
03/05/18
LBT Change of Director's Interest Notice
03/05/18
LBT Notice Under Section 708A
27/04/18
LBT Appendix 3B
27/04/18
LBT Appendix 3B
26/04/18
LBT Quarterly Activities & Cash Flow Report - Appendix 4C
26/04/18PRICE SENSITIVE
LBT First Placement of APAS Independence into European Lab
24/04/18PRICE SENSITIVE
LBT Presentation of APAS Evaluation at 28th ECCMID Conference
23/04/18
LBT EGM - Results of Meeting
18/04/18
LBT EGM - CEO Presentation
18/04/18
LBT Appendix 3B
10/04/18
LBT Share Purchase Plan Raises $0.49M
06/04/18
LBT Notice of Extraordinary General Meeting/Proxy Form
16/03/18
LBT Share Purchase Plan Offer Document
14/03/18PRICE SENSITIVE
LBT NOTICE UNDER SECTION 708A
12/03/18
LBT Information under Listing Rule 3.10.5A
12/03/18
LBT Appendix 3B
12/03/18
LBT $7m Oversubscribed Private Placement & Launch of $1m SPP
06/03/18PRICE SENSITIVE
LBT Trading Halt
02/03/18PRICE SENSITIVE
LBT Half Yearly Report and Accounts
26/02/18PRICE SENSITIVE
LBT LBT Receives $4m Funding from South Australian Government
19/02/18PRICE SENSITIVE
LBT Quarterly Activities & Cash Flow Report (Appendix 4C)
29/01/18PRICE SENSITIVE
LBT LBT Presentation JP Morgan Biotech Showcase
08/01/18
LBT $2.5M Grant Awarded to Advance WoundVue Development
07/12/17PRICE SENSITIVE
LBT Appendix 3B
04/12/17
LBT Change of Director's Interest Notice
01/12/17
LBT Change of Director's Interest Notice
01/12/17
LBT Appendix 3B
01/12/17
LBT Completion of Transaction with Autobio
01/12/17PRICE SENSITIVE
LBT Results of Meeting
29/11/17
LBT CEO Presentation - AGM 2017
29/11/17
LBT Chairman's Address to Shareholders
29/11/17
LBT St Vincent's Hospital Completes APAS Independence Evaluation
29/11/17PRICE SENSITIVE
LBT Appendix 4C - quarterly
31/10/17PRICE SENSITIVE
LBT Autobio $2M Placement in LBT & MicroStreak IP Transfer
27/10/17PRICE SENSITIVE
LBT Notice of Annual General Meeting/Proxy Form
27/10/17
LBT LBT Present at AusBiotech Investor Conference
24/10/17
LBT LBT Receives $4.2 Million in R&D Incentives
09/10/17PRICE SENSITIVE
LBT Appendix 4G and Corporate Governance Statement
29/09/17
LBT Annual Report to shareholders
29/09/17
LBT Shareholder Update
29/09/17
LBT ST Vincent's Hospital Commences APAS Automated Evaluation
27/09/17PRICE SENSITIVE
LBT Initial Director's Interest Notice
01/09/17
LBT Initial Director's Interest Notice
01/09/17
LBT Preliminary Final Report
31/08/17PRICE SENSITIVE
LBT LBT Innovations Appoints New CFO Ray Ridge
25/08/17
LBT LBT's WoundVue Prototype to be used at CALHN
08/08/17PRICE SENSITIVE
LBT Final Director's Interest Notice
01/08/17
LBT CHANGE OF REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS
27/07/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
1.9¢ 		Change
-0.001(5.00%) 		Mkt cap ! $23.13M
Open High Low Value Volume
1.9¢ 1.9¢ 1.9¢ $4.463K 234.8K

Buyers (Bids)

No. Vol. Price($)
3 950618 1.8¢
 

Sellers (Offers)

Price($) Vol. No.
1.9¢ 278267 1
View Market Depth
Last trade - 13.53pm 22/11/2024 (20 minute delay) ?
Last
1.8¢ 		  Change
-0.001 ( 5.26 %)
Open High Low Volume
1.9¢ 1.9¢ 1.8¢ 153983
Last updated 14.57pm 22/11/2024 ?
LBT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.